Amylyx Pharmaceuticals, Inc.
AMLX
Pozycja w akcjach
#4620
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Cena akcji
$26.28
Ostatnia synchronizacja: 2026-10-16
Kapitalizacja rynkowa
$3.30B
Zmiana (1 dzień)
-4.95%
Zmiana (1 rok)
75.79%
Kraj
US
Handel Amylyx Pharmaceuticals, Inc. (AMLX)
Kategoria
Healthcare
EPS dla Amylyx Pharmaceuticals, Inc. (AMLX)
EPS na dzień June 2026 TTM: $-1.41
Według najnowszych raportów finansowych i ceny akcji firmy Amylyx Pharmaceuticals, Inc., obecny EPS (TTM) wynosi $-1.41. Na koniec roku 2023 firma miała EPS w wysokości $0.73, wzrost w porównaniu do do EPS z roku 2022, który wynosił $-2.98.
Historia EPS dla Amylyx Pharmaceuticals, Inc. od 2019 do 2026
EPS na koniec każdego roku
| Rok | EPS | Zmień |
|---|---|---|
| 2026 (TTM) | $-1.41 | -68.17% |
| 2024 | $-4.43 | -706.85% |
| 2023 | $0.73 | -124.50% |
| 2022 | $-2.98 | 96.05% |
| 2021 | $-1.52 | 92.41% |
| 2020 | $-0.79 | 203.85% |
| 2019 | $-0.26 | 0.00% |
EPS dla podobnych firm lub konkurentów
| Firma | EPS | Różnica w EPS | Kraj |
|---|---|---|---|
| $17.32 | -1,328.37% |
US
|
|
| $-7.98 | 465.96% |
US
|
|
| $-5.29 | 275.18% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,067.38% |
NL
|
